Guoke Hengtai (301370.SZ): Junlian Yikang has completed a shareholding reduction of 3%.

On December 23, Gelonghui reported that Guoke Hengtai (301370.SZ) announced that the company recently received a notice from Junlian Yikang regarding the completion of the Shareholding plan for Guoke Hengtai (Peking) Medical Technology Co., Ltd. As of the date of the announcement, Junlian Yikang has reduced its holdings in the company's shares by a total of 14,008,822 shares through centralized bidding, accounting for 3.0000% of the total share capital after excluding the repurchased shares. This Shareholding plan has been completed.

Gelonghui FinanceDec 23, 2024 20:44

Express News | This week, 30 A-shares listed companies disclosed the latest announcements on mergers and acquisitions. Guosen intends to purchase 96.08% shares of Wanhua Securities for 5.192 billion yuan.

BreakingsDec 8, 2024 18:52

Guokexingtai (301370.SZ) plans to liquidate and deregister its holding subsidiary Guokexinghui.

Guoke Hengtai (301370.SZ) issued an announcement, the company held the third session of the Board of Directors meeting respectively on December 2, 2024...

Zhitong FinanceDec 3, 2024 21:06

Guokai Hengtai (301370.SZ) plans to acquire the remaining 40% equity of Guangdong Hengtai.

Guoke Hengtai (301370.SZ) announced that the company plans to use its own funds to acquire Zhanjiang Guangyuantai Medical Investment...

Zhitong FinanceDec 3, 2024 21:04

Guoke Hengtai (301370.SZ): basically covers all categories of medical instruments, except for vascular intervention and orthopedics.

Gelonghui November 27th | Guoke Hengtai (301370.SZ) stated in investor relations that the company has basically covered all categories of medical instruments. In addition to vascular intervention and orthopedics, the company will also focus on major categories such as equipment, IVD, etc., and increase the introduction of manufacturers and corresponding additional services for these two types of products.

Gelonghui FinanceNov 27, 2024 19:47

Guoke Hengtai (301370.SZ): Currently, the company's revenue from imported and domestic medical instruments accounts for approximately 7:3.

On November 27, Gelonghui reported that Guoke Hengtai (301370.SZ) stated in investor relations that the current revenue ratio of imported to domestic medical instruments is approximately 7:3. In terms of customer expansion, the company's innovative platform model has gained widespread recognition from customers and has established cooperation with over a hundred top domestic and foreign medical instrument manufacturers. The company provides manufacturers with high-standard services and high-quality delivery through its nationwide integrated operation capability and complete chain service capability, efficiently meeting the requirements of domestic and foreign customers. Looking to the future, the company will leverage its professional advantages in product services and the reputation established in the industry.

Gelonghui FinanceNov 27, 2024 19:47